Stocks · Healthcare · Medical - Healthcare Plans
Molina Healthcare, Inc. MOH
$189.54 +4.81% Close, Oct 2, 2026 · NYSE · Market cap $9.89B
Low risk
Next earnings report: Oct 21, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.19, down 99.1% year over year.
- The shares trade at 997.6× trailing earnings, higher than 95% of the company's own readings over the past five years.
- The diluted share count fell 5.5% in a year, mainly through buybacks.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 34%
- EPS growth (TTM, YoY)Bottom 18%
- FCF growth (TTM, YoY)Bottom 20%
- Revenue growth, 3-year CAGRTop 45%
- Revenue growth accelerationBottom 26%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 27%
- Gross marginBottom 23%
- Operating marginTop 41%
- Accruals (lower is better)Bottom 26%
- Net debt / EBITDA (lower is better)Top 10%
- Interest coverTop 39%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 30%
- Free-cash-flow yieldTop 27%
- EBITDA / enterprise valueTop 26%
- Sales / enterprise valueTop 1%
- P/E vs own 5-year history (lower is better)Bottom 8%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 38%
- 6-month returnTop 27%
- 1-year return vs S&P 500Bottom 42%
- Distance from 52-week highTop 35%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 11%
- Upside to consensus price targetBottom 16%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 23%
- Maximum drawdown, 3 yearsBottom 49%
- Beta vs S&P 500 (lower is better)Top 2%
- Net debt / EBITDA (lower is better)Top 10%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 7.7% | 2.6% | ↓ |
| EPS growth (YoY) | -81.9% | -99.1% | ↓ |
| Gross margin | 10.9% | 34.6% | ↑ |
| Operating margin | 3.8% | 0.7% | ↓ |
| FCF margin | 1.0% | 0.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 2.6% | 7.7% | ↓ | Bottom 34% |
| EPS growth (TTM, YoY) | -99.1% | -81.9% | ↓ | Bottom 18% |
| Gross margin | 34.6% | 10.9% | ↑ | Bottom 23% |
| Operating margin | 0.7% | 3.8% | ↓ | Top 41% |
| Net margin | -0.0% | 2.6% | ↓ | — |
| Free-cash-flow margin | 0.6% | 1.0% | ↓ | — |
| Return on invested capital | 3.5% | — | Top 27% | |
| Revenue growth, 3-year CAGR | 12.4% | — | Top 45% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.2%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -12.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -2.78×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 5.20%
- Shareholder yield
- 5.20%
- Share count change, 1 year
- -5.5%
- Share count change, 3-year CAGR
- -4.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 23, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.5%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $205.45
- Target vs current price
- +8.4%
- Analysts with a rating
- 39
- Share rating Buy or Strong Buy
- 44%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 22, 2026 | +8.6% | -2.1% | -11.6% | -10.1% | — |
| Apr 22, 2026 | +23.7% | +1.3% | +22.8% | +22.1% | +49.3% |
| Feb 5, 2026 | -739.5% | -0.7% | -31.1% | -17.0% | +8.2% |
| Oct 22, 2025 | -53.7% | -0.8% | -17.3% | -28.3% | -2.7% |
| Jul 23, 2025 | -2.5% | +5.3% | -10.8% | -3.8% | +6.5% |
| Apr 23, 2025 | +1.8% | +3.4% | -0.4% | +1.6% | -43.0% |
| Feb 5, 2025 | -12.0% | +0.5% | -13.4% | -1.1% | -0.8% |
| Oct 23, 2024 | +3.4% | -3.2% | +13.8% | -0.5% | +4.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 22, 2026 | $1.51 | $1.39 | +8.6% | $10.87B |
| Apr 22, 2026 | $2.35 | $1.90 | +23.7% | $10.80B |
| Feb 5, 2026 | -$2.75 | $0.43 | -739.5% | $11.38B |
| Oct 22, 2025 | $1.84 | $3.97 | -53.7% | $11.48B |
| Jul 23, 2025 | $5.48 | $5.62 | -2.5% | $11.43B |
| Apr 23, 2025 | $6.08 | $5.97 | +1.8% | $11.15B |
| Feb 5, 2025 | $5.05 | $5.74 | -12.0% | $10.50B |
| Oct 23, 2024 | $6.01 | $5.81 | +3.4% | $10.34B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 997.6× | 20.2× | 95th | Top 30% |
| P/E (forward) | 36.2× | — | — | — |
| EV / EBITDA | 23.9× | — | — | Top 26% |
| EV / Sales | 0.20× | — | — | Top 1% |
| Free-cash-flow yield | 2.74% | — | — | Top 27% |
| Earnings yield | 0.10% | — | — | Top 30% |
P/E over the past five years
Range 7.8× – 46.7× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -1.7%
- Earnings per share growth (TTM)
- -99.1%
- Change in P/E multiple
- +206.9%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 1
- 50-day average slope (20 days)
- -6.1%
- 200-day average slope (20 days)
- +2.6%
- Distance from 50-day average
- -4.4%
- Distance from 200-day average
- +4.3%
- RSI (14)
- 43.8
- Relative volume
- 1.03×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 41.0%
- Volatility vs own 5-year history
- 65th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- -0.17
- Correlation with S&P 500
- -0.05
- Current drawdown from 1-year high
- -22.0%
- Maximum drawdown, 3 years
- -70.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 19, 2024 | Feb 11, 2026 | -70.8% | 476 days | Not yet recovered |
| Oct 26, 2022 | Mar 15, 2023 | -29.4% | 95 days | 188 days (Dec 12, 2023) |
| Apr 20, 2022 | Jun 17, 2022 | -27.6% | 41 days | 56 days (Sep 8, 2022) |
| Dec 29, 2021 | Jan 26, 2022 | -17.4% | 19 days | 33 days (Mar 15, 2022) |
| Jan 8, 2021 | Feb 8, 2021 | -16.7% | 20 days | 45 days (Apr 14, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $9.89B
- P/E (TTM)
- 997.6
- EPS, diluted (TTM)
- $0.19
- Revenue (TTM)
- $44.52B
- 52-week range
- $121.06 – $244.89
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $27.77B | $31.97B | $34.07B | $40.65B | $45.43B |
| Gross profit | $3.28B | $3.93B | $4.33B | $4.74B | $5.94B |
| Operating income | $1.02B | $1.38B | $1.57B | $1.71B | $781.0M |
| Net income | $659.0M | $792.0M | $1.09B | $1.18B | $472.0M |
| EPS (diluted) | $11.25 | $13.54 | $18.78 | $20.42 | $8.92 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.34B | $10.50B | $11.15B | $11.43B | $11.48B | $11.38B | $10.80B | $10.87B |
| Net income | $326.0M | $251.0M | $298.0M | $255.0M | $79.0M | -$160.0M | $14.0M | $60.0M |
| EPS (diluted) | $5.65 | $4.35 | $5.45 | $4.74 | $1.50 | -$2.77 | $0.27 | $1.19 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.12B | $773.0M | $1.66B | $644.0M | -$535.0M |
| Capital expenditure | -$77.0M | -$91.0M | -$84.0M | -$100.0M | -$101.0M |
| Free cash flow | $2.04B | $682.0M | $1.58B | $544.0M | -$636.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$128.0M | -$400.0M | -$60.0M | -$1.00B | -$1.00B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $8.91B
- Total assets
- $16.00B
- Total liabilities
- $11.83B
- Total debt
- $3.95B
- Net debt
- -$1.03B
- Shareholders’ equity
- $4.17B
As of Jun 30, 2026 (filed Jul 23, 2026).
Short interest
- Shares sold short
- 3,208,457
- Days to cover
- 5.84
- Change vs previous report
- +4.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- May 23, 2011
- 3-for-2